GLP-1 Weight Loss Candidates: Clinical Eligibility & Biomarkers

Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 weight loss treatment is generally appropriate for adults with a BMI of 30 or higher, or 27 or higher with weight-related comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease. Eligibility extends beyond BMI alone to include metabolic risk factors, medication interactions, and individual health goals assessed by a qualified provider.

Determining candidacy for GLP-1 therapy requires more than meeting weight thresholds—it involves understanding your metabolic profile, kidney function, medical history, and whether compounded or branded options align with your clinical picture. PlexusDx supports precision-guided conversations by offering both compounded GLP-1 access and optional genetic testing to explore peptide pathway predispositions.

Core Clinical Eligibility Criteria for GLP-1 Treatment

Standard GLP-1 candidacy is defined by body mass index (BMI) and presence of weight-related conditions. Adults with BMI ≥30 kg/m², or BMI ≥27 with comorbidities like type 2 diabetes, hypertension, or sleep apnea, typically qualify. These thresholds are based on clinical trial evidence and FDA guidance for approved GLP-1 agents.

Beyond BMI, providers evaluate baseline glucose metabolism, liver and kidney function, family history of thyroid or pancreatic disease, and current medications that could interact with GLP-1 receptor agonists. A thorough medical assessment ensures safety and appropriate dosing strategy from the start of treatment.

Key Health Markers That Inform GLP-1 Candidacy Decision

Multiple physiologic and metabolic markers guide provider decisions about GLP-1 suitability. These include fasting glucose, HbA1c, lipid profile, inflammatory markers, and renal function. Some patients benefit from baseline testing to establish a clear metabolic baseline before starting therapy.

Biomarker	Why It Matters for GLP-1 Candidacy
Fasting glucose & HbA1c	Reveals glycemic control status; GLP-1 effects on glucose may require dose or concurrent medication adjustment
Renal function (eGFR)	Determines safe dosing; some GLP-1 agents require caution in moderate-to-severe kidney disease
Lipid profile (LDL, triglycerides)	Shows cardiometabolic risk; GLP-1 often improves triglycerides and lipid patterns
Liver enzymes (ALT, AST)	Screens for liver dysfunction; important baseline before initiating any peptide therapy

Medical Conditions and Medications That Affect Eligibility

Certain medical histories may require extra caution or contraindicate GLP-1 use. These include personal or strong family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, active or recent pancreatitis, and severe gastrointestinal disease. Diabetic retinopathy may require closer monitoring due to rapid glycemic shifts.

Concurrent medications—particularly other diabetes drugs, blood pressure agents, and certain psychiatric medications—can interact with GLP-1 therapy. Providers must review your complete medication list and may adjust dosing or timing. This assessment is essential before starting any compounded or branded GLP-1 product.

Who May Not Be a Candidate and When to Explore Alternatives

Absolute contraindications include personal history of medullary thyroid cancer, MEN2 syndrome, or current pregnancy. Relative contraindications—such as severe renal impairment, active pancreatitis, or uncontrolled psychiatric conditions—require provider discussion and possible alternative therapy. Age alone is not a contraindication, though older adults may require adjusted starting doses.

If you have a complex medical history, prior adverse reactions to peptide therapies, or contraindications to GLP-1 agents, your provider may recommend lifestyle modification alone, other pharmacologic options, or a staged approach. PlexusDx supports these conversations by offering comprehensive assessment resources and access to multiple compounded formulations if GLP-1 is appropriate.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about your individual predispositions in key peptide-signaling pathways, including GLP1R, GIPR, and FTO genetic variants. These predispositions can support a more informed conversation with your provider about whether GLP-1 therapy aligns with your metabolic profile and individual response potential. This information should be interpreted alongside clinical biomarkers and medical history, not in isolation.

The genetic test examines variants such as GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—all linked to appetite regulation and metabolic function. Understanding these predispositions does not predict your exact medication response, but may illuminate which patients have genetic factors supporting GLP-1 pathway engagement. This knowledge can help tailor dosing strategy and treatment expectations with your healthcare provider.

When combined with clinical assessment, genetic insights can deepen the candidacy conversation. Rather than viewing GLP-1 as a one-size-fits-all option, a personalized approach considers your biomarkers, medical history, and genetic predispositions together. PlexusDx helps eligible patients access compounded GLP-1 options while supporting provider-led, precision-guided treatment decisions.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What BMI thresholds does this article give for GLP-1 candidacy?

The article says GLP-1 treatment is generally appropriate for adults with a BMI of 30 or higher, or 27 or higher when weight-related comorbidities such as type 2 diabetes, hypertension, sleep apnea, or cardiovascular disease are present. It traces those thresholds to clinical trial evidence and FDA guidance for approved GLP-1 agents. Eligibility, though, extends well beyond the number itself.

Why does the article's biomarker table include liver enzymes alongside glucose and kidney markers?

The table lists ALT and AST as a screen for liver dysfunction, calling it an important baseline before initiating any peptide therapy. Alongside it the table covers fasting glucose and HbA1c for glycemic control status, eGFR for safe dosing in kidney disease, and a lipid profile for cardiometabolic risk. Those four rows are what the post says give a provider a clear metabolic starting point.

Which conditions does the post treat as absolute rather than relative contraindications?

The article names a personal history of medullary thyroid cancer, MEN2 syndrome, and current pregnancy as absolute contraindications. It puts severe renal impairment, active pancreatitis, and uncontrolled psychiatric conditions in the relative category, requiring provider discussion and possibly an alternative therapy. It adds that age alone is not a contraindication, though older adults may need an adjusted starting point.

Which medication categories does the article say must be reviewed before treatment starts?

The post says concurrent medications, particularly other diabetes drugs, blood pressure agents, and certain psychiatric medications, can interact with GLP-1 therapy. It says providers must review your complete medication list and may change dosing or timing as a result. That review applies whether the product under consideration is compounded or branded.

What does the article suggest for people who turn out not to be candidates?

The article says that for patients with a complex medical history, prior adverse reactions to peptide therapies, or contraindications to GLP-1 agents, a provider may recommend lifestyle modification alone, other pharmacologic options, or a staged approach. It also flags diabetic retinopathy as needing closer monitoring because of rapid glycemic shifts. The alternative path remains a provider-led conversation.

Related Reading

• Glp 1 For Weight Loss 2
• Glp 1 Weight Loss Before And After
• Glp 1 Dosage For Weight Loss
• Glp 1 Receptor Agonist For Weight Loss

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.